- Home
- LDP vs KROS Comparison
LDP vs KROS Comparison
Compare LDP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- KROS
- Stock Information
- Founded
- LDP 2012
- KROS 2015
- Country
- LDP United States
- KROS United States
- Employees
- LDP N/A
- KROS N/A
- Industry
- LDP Finance Companies
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- KROS Health Care
- Exchange
- LDP Nasdaq
- KROS Nasdaq
- Market Cap
- LDP 607.2M
- KROS 589.8M
- IPO Year
- LDP N/A
- KROS 2020
- Fundamental
- Price
- LDP $20.39
- KROS $10.86
- Analyst Decision
- LDP
- KROS Buy
- Analyst Count
- LDP 0
- KROS 11
- Target Price
- LDP N/A
- KROS $45.33
- AVG Volume (30 Days)
- LDP 102.5K
- KROS 1.9M
- Earning Date
- LDP 01-01-0001
- KROS 02-26-2025
- Dividend Yield
- LDP 7.91%
- KROS N/A
- EPS Growth
- LDP N/A
- KROS N/A
- EPS
- LDP N/A
- KROS N/A
- Revenue
- LDP N/A
- KROS $651,000.00
- Revenue This Year
- LDP N/A
- KROS $303.39
- Revenue Next Year
- LDP N/A
- KROS N/A
- P/E Ratio
- LDP N/A
- KROS N/A
- Revenue Growth
- LDP N/A
- KROS 8037.50
- 52 Week Low
- LDP $16.16
- KROS $9.78
- 52 Week High
- LDP $20.30
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- LDP 46.80
- KROS 20.25
- Support Level
- LDP $20.11
- KROS $9.78
- Resistance Level
- LDP $20.66
- KROS $16.49
- Average True Range (ATR)
- LDP 0.24
- KROS 0.92
- MACD
- LDP 0.03
- KROS 0.97
- Stochastic Oscillator
- LDP 61.43
- KROS 14.52
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.